
Stylus Medicine Launches to Advance Precision In Vivo Genetic Medicines
$85 million in financing includes recent $45 million Series A extension with participation from founding investors RA Capital Management and Khosla Ventures and six new
$85 million in financing includes recent $45 million Series A extension with participation from founding investors RA Capital Management and Khosla Ventures and six new
Collaboration supports manufacture of the OPTF01 product to Drive Next-Generation Chimeric Antigen Receptor T Cell (CAR-T) Development Genezen, a leading viral vector Contract Development and Manufacturing
Fuel up with free Health Tech Insights